Balchem Corp. 10-Q Summary: Period Ended June 30, 2010
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Balchem Corporation, a developer, manufacturer, and distributor of specialty performance ingredients for food, nutritional, pharmaceutical, animal health, and medical device sterilization industries. The report covers the three and six months ended June 30, 2010. The company operates through three segments: Specialty Products, Food, Pharma & Nutrition, and Animal Nutrition & Health.
Key Financial Metrics
| Metric (Six Months Ended June 30, 2010) | Value ($ in thousands) |
|---|---|
| Net Sales | $121,361 |
| Gross Margin | $36,530 (30.1%) |
| Operating Income | $22,935 (18.9%) |
| Net Earnings | $15,368 |
| Diluted EPS | $0.52 |
| Cash and Cash Equivalents | $50,374 |
| Working Capital | $77,130 |
| Total Debt (Current + Long-term) | $5,123 |
| Operating Cash Flow | $15,547 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 14.5% to $121.4 million for the six months ended June 30, 2010, compared to $106.0 million in the prior year period. Growth was driven by volume increases across all segments, particularly in Animal Nutrition & Health (+14.5%) and Food, Pharma & Nutrition (+18.1%).
- Profitability: Net earnings rose 18.5% to $15.4 million. Operating income increased 17.0% to $22.9 million.
- Margins: Gross margin percentage decreased slightly to 30.1% from 31.7% in the prior year, primarily due to higher petro-chemical based raw material costs. Operating margin improved to 18.9% from 18.5% due to volume leverage and reduced operating expenses.
- Acquisition: The company acquired a marketer and distributor of propylene oxide for $4.6 million, contributing to sales growth in the Specialty Products segment.
- Debt Reduction: The company paid off its $29 million Term Loan in full. Total debt outstanding was $5.1 million (European Term Loan), with no outstanding revolver borrowings.
Outlook, Risks, and Management Commentary
- Management Commentary: Management attributes sales growth to increased volumes in domestic food sectors, improved dairy economics supporting animal nutrition sales, and the recent propylene oxide acquisition. They note that higher raw material costs are offsetting some margin benefits.
- Liquidity: The company maintains strong liquidity with $50.4 million in cash. Working capital increased by $17.9 million year-over-year. Management expects operations to generate sufficient cash flow for working capital and capital investments.
- Risks and Contingencies:
- Raw Material Costs: Exposure to petro-chemical price fluctuations impacts gross margins.
- Foreign Currency: Strength of the U.S. dollar negatively impacted Euro-denominated sales.
- Environmental: Ongoing monitoring of a former Superfund site in Verona, Missouri (remediation deemed complete by prior owner, company indemnified) and a drum burial site in Slate Hill, New York (monitoring costs are minimal).
- Capital Allocation: The company paid $3.1 million in dividends and spent $4.5 million on capital expenditures. No shares were repurchased during the period.
Investor Verification Checklist
- Verify the sustainability of volume growth in the Animal Nutrition & Health segment given the cyclical nature of dairy economics.
- Monitor petro-chemical raw material costs and their impact on gross margins, which compressed slightly in the period.
- Confirm the integration and revenue contribution of the recent propylene oxide distributor acquisition.
- Review the status of the European Term Loan ($5.1 million outstanding) and renewal terms of credit facilities.
- Assess the impact of foreign exchange rates on international sales, particularly in Europe.